68 maintained documents
The documentation commons page 2
This is the part of the site we are most proud of. When a topic keeps being re-asked, the community promotes it: the content moves onto a page with named maintainers, a revision history, a review date, and a backlink to the discussion it came from. Promotions are argued in doc review in public, and a page nobody will maintain does not get promoted.
68Documents
26,731Words
68With a source topic
0Past review date
| Document | Words | Updated | Review due |
|---|---|---|---|
|
Retatrutide phase 2 (obesity) — trial digest
Retatrutide phase 2 (obesity) (N Engl J Med 2023): What is the dose-response for retatrutide on body weight? |
329 | 17 Jul 2025 | 25 Aug 2026 |
|
Retatrutide phase 2 (type 2 diabetes) — trial digest
Retatrutide phase 2 (type 2 diabetes) (Lancet 2023): What glycaemic and weight effect does retatrutide have in type 2 diabetes? |
294 | 24 May 2026 | 1 Nov 2026 |
|
Reversed-phase HPLC for peptides
Separating a peptide from its related substances and quantifying the result as area percent. |
431 | 3 Aug 2025 | 10 Jun 2027 |
|
SCALE — trial digest
SCALE (N Engl J Med 2015): What weight reduction does liraglutide 3.0 mg achieve? |
284 | 17 Aug 2025 | 6 May 2027 |
|
SELECT — trial digest
SELECT (N Engl J Med 2023): Does semaglutide reduce major adverse cardiovascular events in people without diabetes? |
379 | 3 Jul 2026 | 26 Nov 2026 |
|
Semaglutide — reference
Semaglutide: glp-1 receptor agonist, approximate mass 4113.6 Da, 165–184 h (about one week) half-life. Identity, evidence base, analytical considerations and limitations. |
636 | 8 Feb 2026 | 17 Apr 2027 |
|
Semaglutide in MASH (phase 2) — trial digest
Semaglutide in MASH (phase 2) (N Engl J Med 2021): Does semaglutide achieve resolution of steatohepatitis without worsening of fibrosis? |
332 | 23 Feb 2026 | 30 May 2027 |
|
SOUL — trial digest
SOUL (N Engl J Med 2025): Does the oral formulation deliver cardiovascular benefit comparable to the injectable? |
327 | 6 Dec 2025 | 3 Oct 2026 |
|
STEP 1 — trial digest
STEP 1 (N Engl J Med 2021): Does semaglutide 2.4 mg weekly reduce body weight in adults with obesity and no diabetes? |
388 | 26 Apr 2026 | 29 Sep 2026 |
|
STEP 2 — trial digest
STEP 2 (Lancet 2021): What weight reduction does semaglutide 2.4 mg achieve in people who also have type 2 diabetes? |
326 | 29 Aug 2025 | 7 Feb 2027 |
|
STEP 3 — trial digest
STEP 3 (JAMA 2021): What does semaglutide add on top of intensive behavioural therapy? |
346 | 9 Apr 2026 | 27 Jan 2027 |
|
STEP 4 — trial digest
STEP 4 (JAMA 2021): What happens if you stop after reaching the maintenance dose? |
340 | 17 Jun 2026 | 29 Apr 2027 |
|
STEP 8 — trial digest
STEP 8 (JAMA 2022): How does weekly semaglutide compare directly with daily liraglutide? |
334 | 25 Feb 2026 | 13 Jan 2027 |
|
STEP-HFpEF — trial digest
STEP-HFpEF (N Engl J Med 2024): Does semaglutide improve symptoms and physical limitation in obesity-related HFpEF? |
300 | 16 Apr 2026 | 1 Jan 2027 |
|
SURMOUNT-1 — trial digest
SURMOUNT-1 (N Engl J Med 2022): What weight reduction does tirzepatide achieve in obesity? |
325 | 15 Jul 2026 | 21 May 2027 |
|
SURMOUNT-4 — trial digest
SURMOUNT-4 (JAMA 2024): What happens when tirzepatide is withdrawn after maintenance is reached? |
301 | 29 Jun 2026 | 19 Aug 2026 |
|
SURMOUNT-OSA — trial digest
SURMOUNT-OSA (N Engl J Med 2024): Does tirzepatide reduce the apnoea-hypopnoea index? |
325 | 26 Feb 2026 | 9 Nov 2026 |
|
SURPASS-2 — trial digest
SURPASS-2 (N Engl J Med 2021): How does tirzepatide compare directly with semaglutide for glycaemic control and weight? |
320 | 9 Jul 2026 | 1 Sep 2026 |
|
SURPASS-4 — trial digest
SURPASS-4 (Lancet 2021): How does tirzepatide compare with basal insulin in a higher-risk diabetes population? |
312 | 18 Oct 2025 | 1 Apr 2027 |
|
Survodutide — reference
Survodutide: dual glucagon and glp-1 receptor agonist, approximate mass —, Suitable for weekly dosing half-life. Identity, evidence base, analytical considerations and limitations. |
500 | 14 May 2026 | 20 Jan 2027 |
|
SUSTAIN 6 — trial digest
SUSTAIN 6 (N Engl J Med 2016): Is semaglutide cardiovascular-safe in high-risk type 2 diabetes, and is there benefit? |
331 | 15 Feb 2026 | 3 Nov 2026 |
|
System suitability testing
Establishing that the instrument, column and method were performing when the sample was run. |
348 | 24 Apr 2026 | 1 Dec 2026 |
|
TB-500 — reference
TB-500: thymosin beta-4 fragment (research use only), approximate mass 889.0 Da (the commonly sold 7-residue fragment), Not well characterised in humans half-life. Identity, evidence base, analytical considerations and limitations. |
523 | 25 Apr 2026 | 3 Oct 2026 |
|
Tesamorelin — reference
Tesamorelin: ghrh analogue, approximate mass 5135.8 Da, 26–38 min half-life. Identity, evidence base, analytical considerations and limitations. |
496 | 26 Jun 2026 | 21 Aug 2026 |
|
Tirzepatide — reference
Tirzepatide: dual gip and glp-1 receptor agonist, approximate mass 4813.5 Da, 5 days half-life. Identity, evidence base, analytical considerations and limitations. |
598 | 26 Nov 2025 | 10 Jan 2027 |
|
UV and diode-array detection
Knowing what the detector responds to, and using peak purity properly. |
359 | 2 Jul 2026 | 7 Oct 2026 |
|
VendorInvestigate — what its reports establish
VendorInvestigate: Documentation and supplier-practice review. What a report from this service does and does not establish, and how we cite it. |
311 | 11 Apr 2026 | 18 Nov 2026 |
|
Water content by Karl Fischer titration
Quantifying residual water in lyophilised material, which changes every mass-based calculation. |
321 | 17 Jul 2026 | 7 Apr 2027 |